OBJECTIVE: To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. METHOD: Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8-week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2-point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. RESULTS: Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). CONCLUSIONS: The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms.
OBJECTIVE: To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. METHOD: Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8-week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2-point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. RESULTS: Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P = .054). CONCLUSIONS: The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms.
Authors: Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Benji Kurian; Sidney Zisook; Susan G Kornstein; Edward S Friedman; Sachiko Miyahara; Andrew F Leuchter; Maurizio Fava; A John Rush Journal: J Clin Psychopharmacol Date: 2010-06 Impact factor: 3.153
Authors: A J Rush; M H Trivedi; T J Carmody; R M Donahue; T L Houser; C Bolden-Watson; S R Batey; J A Ascher; A Metz Journal: Neuropsychopharmacology Date: 2001-07 Impact factor: 7.853
Authors: M H Trivedi; A J Rush; T J Carmody; R M Donahue; C Bolden-Watson; T L Houser; A Metz Journal: J Clin Psychiatry Date: 2001-10 Impact factor: 4.384
Authors: Maurizio Fava; A John Rush; Madhukar H Trivedi; Andrew A Nierenberg; Michael E Thase; Harold A Sackeim; Frederic M Quitkin; Steven Wisniewski; Philip W Lavori; Jerrold F Rosenbaum; David J Kupfer Journal: Psychiatr Clin North Am Date: 2003-06
Authors: C O'Driscoll; J E J Buckman; E I Fried; R Saunders; Z D Cohen; G Ambler; R J DeRubeis; S Gilbody; S D Hollon; T Kendrick; D Kessler; G Lewis; E Watkins; N Wiles; S Pilling Journal: BMC Med Date: 2021-05-06 Impact factor: 8.775
Authors: Sudhakar Selvaraj; Chris Walker; Danilo Arnone; Bo Cao; Paul Faulkner; Philip J Cowen; Jonathan P Roiser; Oliver Howes Journal: Neuropsychopharmacology Date: 2017-08-04 Impact factor: 7.853